RT Journal Article
SR Electronic
T1 Coagulopathy in patients with Coronavirus Disease 2019 (COVID-19): A systematic review and meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.15.20154138
DO 10.1101/2020.07.15.20154138
A1 Zhang, Xiaolin
A1 Yang, Xue
A1 Jiao, Hongmei
A1 Liu, Xinmin
YR 2020
UL http://medrxiv.org/content/early/2020/07/16/2020.07.15.20154138.abstract
AB Patients with COVID-19 frequently manifest coagulation abnormalities and thrombotic events. In this meta-analysis, we aimed to explore the role of coagulopathy on the severity differences in patients with COVID-19. We conducted systematic literature search via Pubmed, Embase, Cochrane, WanFang Database, CNKI, and medRxiv from December 1, 2019 to May 1, 2020, to identify all original studies that reports on coagulation parameters (D-dimer, PLT, PT, APTT, and FIB) during COVID-19 infection. Thereafter, we compared the coagulation parameters between less severe and more severe cases. All Statistical analyses were performed via Stata14.0 software. A total of 3,952 confirmed COVID-19 infected patients were included from 25 studies. Patients with severe COVID-19 infection exhibited significantly higher levels of D-dimer, PT, and FIB (SMD 0.83, 95% CI: 0.70-0.97, I2 56.9%; SMD 0.39, 95% CI: 0.14-0.64, I2 77.9%; SMD 0.35, 95% CI: 0.17-0.53, I242.4% respectively). However, difference in PLT and APTT levels between less severe and more severe patients was not statistically significant (SMD-0.26, 95% CI:-0.56-0.05, I2 82.2%; SMD-0.14,95% CI: −0.45-0.18, I2 75.5% respectively) This meta-analysis revealed coagulopathy is associated with the severity of COVID-19. Notably, D-dimer, PT, and FIB are the dominant parameters that should be considered in evaluating coagulopathy in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was also approved by your Institutional Ethics Committe.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are fully available without restriction.Acronyms and AbbreviationsACE2Angiotensin-Converting Enzyme 2APTTActivated partial thromboplastin timeARDSAcute respiratory distress syndromeCACCOVID-19 associated coagulopathyCIConfidence intervalCOVID-19Coronavirus disease 2019DICDisseminated intravascular coagulationFIBFibrinogenLMWHLow molecular weight heparinMERSMiddle East Respiratory SyndromeNOACNew oral anticoagulantPLTPlateletPTProthrombin timeSARSSevere Acute Respiratory SyndromeSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2SDStandard deviationSMDStandard mean difference